Todd C. Davis - 15 Feb 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis
Issuer symbol
LGND
Transactions as of
15 Feb 2024
Transactions value $
-$103,092
Form type
4
Filing time
16 Feb 2024, 20:10:16 UTC
Previous filing
25 Sep 2023
Next filing
23 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Tax liability -$103K -1.38K -1.89% $74.65 71.7K 15 Feb 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.